TECH BIO-TECHNE Corp

Price (delayed)

$73.575

Market cap

$11.57B

P/E Ratio

52.18

Dividend/share

$0.32

EPS

$1.41

Enterprise value

$11.99B

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
BIO-TECHNE's equity has increased by 7% YoY
The revenue has grown by 2.2% YoY
TECH's P/E is 16% below its 5-year quarterly average of 63.1 but 13% above its last 4 quarters average of 46.6
BIO-TECHNE's debt has surged by 92% YoY
TECH's EPS is down by 16% year-on-year and by 10% since the previous quarter

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
157.19M
Market cap
$11.57B
Enterprise value
$11.99B
Valuations
Price to book (P/B)
5.93
Price to sales (P/S)
10.12
EV/EBIT
45.65
EV/EBITDA
32.16
EV/Sales
10.47
Earnings
Revenue
$1.14B
EBIT
$262.67M
EBITDA
$372.91M
Free cash flow
$225.39M
Per share
EPS
$1.41
Free cash flow per share
$1.43
Book value per share
$12.42
Revenue per share
$7.27
TBVPS
$7.62
Balance sheet
Total assets
$2.73B
Total liabilities
$767.19M
Debt
$555.7M
Equity
$1.96B
Working capital
$455.41M
Liquidity
Debt to equity
0.28
Current ratio
4.37
Quick ratio
2.54
Net debt/EBITDA
1.14
Margins
EBITDA margin
32.6%
Gross margin
67.1%
Net margin
19.6%
Operating margin
23.5%
Efficiency
Return on assets
8.4%
Return on equity
11.5%
Return on invested capital
18.3%
Return on capital employed
10.1%
Return on sales
22.9%
Dividend
Dividend yield
0.43%
DPS
$0.32
Payout ratio
22.7%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
-1.1%
1 week
2.53%
1 month
1.09%
1 year
1.29%
YTD
-4.65%
QTD
-4.65%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.14B
Gross profit
$768.64M
Operating income
$268.6M
Net income
$224.16M
Gross margin
67.1%
Net margin
19.6%
BIO-TECHNE's net margin has decreased by 16% YoY and by 9% QoQ
The net income has decreased by 14% YoY and by 9% from the previous quarter
BIO-TECHNE's operating margin has decreased by 11% YoY and by 10% QoQ
The company's operating income fell by 10% QoQ and by 9% YoY

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
52.18
P/B
5.93
P/S
10.12
EV/EBIT
45.65
EV/EBITDA
32.16
EV/Sales
10.47
TECH's EPS is down by 16% year-on-year and by 10% since the previous quarter
TECH's P/E is 16% below its 5-year quarterly average of 63.1 but 13% above its last 4 quarters average of 46.6
The stock's price to book (P/B) is 22% less than its 5-year quarterly average of 7.7
BIO-TECHNE's equity has increased by 7% YoY
The price to sales (P/S) is 21% lower than the 5-year quarterly average of 13.0
The revenue has grown by 2.2% YoY

Efficiency

How efficient is BIO-TECHNE business performance
BIO-TECHNE's ROIC has decreased by 49% YoY and by 20% from the previous quarter
TECH's return on assets is down by 26% year-on-year and by 12% since the previous quarter
BIO-TECHNE's return on equity has decreased by 23% YoY and by 10% QoQ
TECH's return on sales is down by 22% year-on-year and by 11% since the previous quarter

Dividends

What is TECH's dividend history
DPS
$0.32
Dividend yield
0.43%
Payout ratio
22.7%
Recent dividends

Financial health

How did BIO-TECHNE financials performed over time
BIO-TECHNE's total liabilities has increased by 43% YoY
TECH's total assets is up by 16% year-on-year
BIO-TECHNE's debt is 72% lower than its equity
BIO-TECHNE's debt has surged by 92% YoY
TECH's debt to equity has soared by 75% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.